Literature DB >> 7891375

Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity.

P Heutink1, T Haitjema, G J Breedveld, B Janssen, L A Sandkuijl, C J Bontekoe, C J Westerman, B A Oostra.   

Abstract

Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant disorder with unknown pathophysiology that is characterised by arteriovenous lesions and recurrent haemorrhage in virtually every organ. Linkage of HHT to markers on chromosome 9q has recently been reported. In this study we report confirmation of this localisation in three unrelated families of Dutch origin. A fourth unrelated HHT family, in which considerably fewer pulmonary arteriovenous malformations (PAVM) were present, yielded evidence for non-linkage to this region. We conclude that HHT is a genetically heterogeneous disorder and our results indicate that the presence of PAVM may be more common in patients with a chromosome 9 linked form of HHT than in patients with the non-linked form.

Entities:  

Mesh:

Year:  1994        PMID: 7891375      PMCID: PMC1016693          DOI: 10.1136/jmg.31.12.933

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  18 in total

1.  A family reunion: a study of hereditary hemorrhagic telangiectasia.

Authors:  R M BIRD; J F HAMMARSTEN; R A MARSHALL; R R ROBINSON
Journal:  N Engl J Med       Date:  1957-07-18       Impact factor: 91.245

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population.

Authors:  H Plauchu; J P de Chadarévian; A Bideau; J M Robert
Journal:  Am J Med Genet       Date:  1989-03

4.  Hereditary hemorrhagic telangiectasy (HHT) and HLA.

Authors:  A Sensi; V Abbasciano; A Balboni; F Levato; O R Baricordi
Journal:  Tissue Antigens       Date:  1986-11

5.  Management of epistaxis in Osler-Weber-Rendu disease: recurrence of telangiectases within a nasal skin graft.

Authors:  W P McCabe; A P Kelly
Journal:  Plast Reconstr Surg       Date:  1972-08       Impact factor: 4.730

6.  Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction.

Authors:  J L Weber; P E May
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

7.  Clinical manifestations of hereditary hemorrhagic telangiectasia.

Authors:  P J Reilly; T T Nostrant
Journal:  Am J Gastroenterol       Date:  1984-05       Impact factor: 10.864

8.  Analysis of the relationship of von Willebrand disease (vWD) and hereditary hemorrhagic telangiectasia and identification of a potential type IIA vWD mutation (IIe865 to Thr).

Authors:  M C Iannuzzi; N Hidaka; M Boehnke; M E Bruck; W T Hanna; F S Collins; D Ginsburg
Journal:  Am J Hum Genet       Date:  1991-04       Impact factor: 11.025

Review 9.  Clinical spectrum of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease).

Authors:  W H Peery
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

10.  Strategies for multilocus linkage analysis in humans.

Authors:  G M Lathrop; J M Lalouel; C Julier; J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

View more
  12 in total

Review 1.  Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.

Authors:  C L Shovlin; M Letarte
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1.

Authors:  A Bourdeau; U Cymerman; M E Paquet; W Meschino; W C McKinnon; A E Guttmacher; L Becker; M Letarte
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin?

Authors:  J N Berg; A E Guttmacher; D A Marchuk; M E Porteous
Journal:  J Med Genet       Date:  1996-03       Impact factor: 6.318

4.  A murine model of hereditary hemorrhagic telangiectasia.

Authors:  A Bourdeau; D J Dumont; M Letarte
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

5.  The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2.

Authors:  J N Berg; C J Gallione; T T Stenzel; D W Johnson; W P Allen; C E Schwartz; C E Jackson; M E Porteous; D A Marchuk
Journal:  Am J Hum Genet       Date:  1997-07       Impact factor: 11.025

6.  [Hereditary hemorrhagic telangiectasia. A rare treatable cause of stroke].

Authors:  D Ecker; U W Geisthoff; M Juchems; G Schneider; A C Ludolph; J Kassubek; R Huber
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

Review 7.  Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures.

Authors:  Haneen Sadick; Maliha Sadick; Karl Götte; Ramin Naim; Frank Riedel; Gregor Bran; Karl Hörmann
Journal:  Wien Klin Wochenschr       Date:  2006-03       Impact factor: 1.704

8.  Visceral manifestations in hereditary haemorrhagic telangiectasia type 2.

Authors:  S A Abdalla; U W Geisthoff; D Bonneau; H Plauchu; J McDonald; S Kennedy; M E Faughnan; M Letarte
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

9.  Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative.

Authors:  N Pece; S Vera; U Cymerman; R I White; J L Wrana; M Letarte
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

10.  Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2.

Authors:  M Piantanida; E Buscarini; C Dellavecchia; A Minelli; A Rossi; L Buscarini; C Danesino
Journal:  J Med Genet       Date:  1996-06       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.